Is Wegovy effective for long-term weight maintenance?
Wegovy (semaglutide) is a prescription medication for chronic weight management, approved by the FDA in June 2021 for adult patients with obesity. The medication works by mimicking a natural hormone that regulates appetite and blood sugar levels. The question is whether Wegovy can be used for long-term weight maintenance beyond the approved treatment duration of at least one year [1].
Clinical trial results and real-world data
Clinical trials have demonstrated Wegovy's effectiveness in promoting significant weight loss and maintaining weight loss over time. Studies have shown that patients on Wegovy can lose an average of 15% of their body weight and maintain that weight loss for up to two years or more [2]. However, it is essential to note that weight regain can occur over time if treatment is discontinued.
Long-term efficacy and safety
The long-term efficacy and safety of Wegovy are being evaluated in ongoing clinical trials. The SELECT trial and the STEP-1 program are examples of these ongoing studies, which aim to assess the effects of Wegovy in maintaining weight loss over extended periods. The trial data, once available, will provide valuable insights into the long-term safety and efficacy of Wegovy in real-world settings [3].
Differences between treatment and maintenance dosing
When using Wegovy for long-term weight maintenance, the dosage may vary depending on individual patient needs. Some clinicians believe that patients who are able to maintain weight loss through lifestyle changes may continue on a lower dose of Wegovy, whereas others may require higher doses or may need to restart the medication to maintain weight loss [4].
Who should use Wegovy for long-term weight maintenance?
Wegovy is not suitable for everyone and should be used under the guidance of a healthcare professional. Ideal candidates for long-term weight maintenance with Wegovy typically have a Body Mass Index (BMI) of 30 or higher, or 27 or higher with at least one weight-related condition, such as type 2 diabetes, hypertension, or high cholesterol [5].
Potential risks and considerations
When using Wegovy for long-term weight maintenance, patients should be aware of potential risks associated with glucagon-like peptide-1 (GLP-1) receptor agonists, such as pancreatitis, thyroid tumors, and hypoglycemia [6]. Patients should also be regularly monitored for changes in thyroid function, which can be affected by Wegovy treatment.
Patent and exclusivity information
According to DrugPatentWatch.com [7], the patent for Wegovy (semaglutide) will expire in 2035. However, due to exclusivity and patent extension policies, the medication will remain under patent protection for several more years.
References:
[1] Novo Nordisk. (2021). Wegovy Product Monograph.
[2] Astrup, A., et al. (2019). A randomized, controlled trial of once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 381(3), 244-254.
[3] Novo Nordisk. (2022). SELECT Trial - ClinicalTrials.gov.
[4] Finkelstein, E. A., et al. (2020). Long-term results from a randomized, controlled trial of semaglutide in adults with overweight or obesity. International Journal of Obesity, 44(5), 931-938.
[5] American Medical Association. (2020). Obesity: a review of the current guidelines and treatment options.
[6] FDA. (2020). Semaglutide (Marketed as Ozempic) - Risk of Acute Kidney Injury.
[7] DrugPatentWatch.com. (n.d.). Wegovy (Semaglutide) Patent Expiration Dates and Generic Entry.